0001492422 2026-04-21 0001492422 2025-01-01 2025-12-31 0001492422 2025-06-30 shares iso4217:USD true 0001492422 FY 10-K/A true 2025-12-31 --12-31 2025 false 001-38276 APELLIS PHARMACEUTICALS, INC. DE 27-1537290 100 Fifth Avenue Waltham MA 02451 617 977-5700 Common Stock, $0.0001 par value per share APLS NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false false 1800000000 128021277 DOCUMENTS INCORPORATED BY REFERENCENone. EXPLANATORY NOTE This Amendment No. 1 on Form 10-K/A (this “Amendment” or “Report”) is filed with respect to our Annual Report on Form 10-K for the year ended December 31, 2025 (the “Original Filing”), filed with the Securities and Exchange Commission (the “SEC”) on February 24, 2026. We are filing this Amendment solely for the purpose of including the information required by Part III of Form 10-K, which information was omitted from the Original Filing in reliance on General Instruction G(3) to Form 10-K, which permits the information required by Part III of Form 10-K to be incorporated by reference from a registrant’s definitive proxy statement if it is filed with the SEC no later than 120 days after the fiscal year end. However, we do not intend to file a definitive proxy statement for our 2026 annual meeting of stockholders within 120 days of the end of our fiscal year ended December 31, 2025. Accordingly, this Amendment is being filed solely to (i) provide the information required by Items 10 through 14 of Part III of the Original Filing, and (ii) delete the reference on the cover page of the Original Filing to the incorporation by reference of portions of our definitive proxy statement into Part III of the Original Filing. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), new certifications by our principal executive officer and principal financial officer are filed herewith as exhibits to this Amendment pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act. This Amendment speaks as of the date of the Original Filing and, except as described above, this Amendment makes no changes to the Original Filing. This Amendment does not amend, update or change the financial statements or any other information presented in the Original Filing and does not otherwise reflect events occurring after the date of the Original Filing. Accordingly, this Amendment should be read in conjunction with our filings with the SEC subsequent to the filing of the Original Filing. Unless indicated otherwise, throughout this Amendment, references to “Apellis,” “the Company,” “we,” “us” and “our” refer Apellis Pharmaceuticals, Inc. and its subsidiaries, except where the context otherwise requires or indicates. true